Background: Depression is one on the most common psychological problems encountered in medical practice. Conventional antidepressants, although effective, have many side effects and there is a need for effective medications with fewer side effects.
Objective: To present all the available clinical evidence on the supplement, S-adenosylmethionine (SAMe) in the treatment of depressive symptoms as well as its safety.
Discussion: Recent clinical studies have revealed that SAMe, a naturally occurring molecule, is safe and effective in the treatment of mild and moderate depression. Although further research is required to clarify SAMe's role as a potential first line treatment for depression, physicians should be aware of the safety and efficacy of SAMe in order to advise patients on its appropriate use as complementary or as an alternative to traditional therapy for depression.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.
Neuropsychopharmacol Rep
March 2025
Department of Neuropsychiatry, Kyorin University Faculty of Medicine, Tokyo, Japan.
Background: Mild depression lacks a consistent definition across diagnostic criteria and rating scales, posing challenges to standardizing treatment strategies. International guidelines predominantly recommend psychotherapy as the first-line treatment for mild depression, while the use of antidepressants remains contentious. Supplements such as omega-3 fatty acids, St.
View Article and Find Full Text PDFArticle Synopsis
- This review evaluates S-adenosylmethionine (SAMe) as a potential alternative treatment for people with depression who don't respond well to standard antidepressants.
- It explores how SAMe may help alleviate depression by influencing neurotransmitter levels, decreasing inflammation in the brain, promoting brain adaptability, and regulating how genes express.
- The review also discusses SAMe's possible benefits for other mental health issues and neurological conditions.
A new strategy for enhancing S-Adenosyl-L-Methionine (SAMe) oral bioavailability: Preparation of SAMe loaded inulin nanoparticles for colon targeting with in vivo validation.
Int J Biol Macromol
February 2025
Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, Turkey. Electronic address:
S-Adenosylmethionine (SAMe) is a crucial endogenous molecule in vital biochemical processes such as DNA, RNA, and protein methylation. It has been found beneficial in the treatment of liver disease, osteoarthritis, and particularly depression. However, SAMe's therapeutic potential is limited by low bioavailability due to poor permeability and extensive liver metabolism.
View Article and Find Full Text PDFF. prausnitzii potentially modulates the association between citrus intake and depression.
Microbiome
November 2024
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Background: The gut microbiome modulates the effects of diet on host health, but it remains unclear which specific foods and microbial features interact to influence risk of depression. To understand this interplay, we leveraged decades of dietary and depression data from a longitudinal cohort of women (n = 32,427), along with fecal metagenomics and plasma metabolomics from a substudy (n = 207) nested in this cohort, as well as an independent validation cohort of men (n = 307).
Results: We report that citrus intake and its components are prospectively associated with a lower risk of depression and altered abundance of 15 gut microbial species, including enriched Faecalibacterium prausnitzii.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!